Please assess the completion status of the following clinical trial:

Trial Title: A Study to Test Whether Different Doses of BI 456906 Are Effective in Treating Adults With Type 2 Diabetes.

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE2
- Number of Arms: 8.0

Eligibility Criteria:
Inclusion criteria:~* Signed and dated written informed consent in accordance with International conference on harmonization - Good clinical practice (ICH GCP) and local legislation.~* Male and female patients 18 years to 75 years (both inclusive) of age on the day of signing informed consent.~* Diagnosis of Type 2 diabetes mellitus (T2DM) at least 6 months prior to informed consent.~* Glycosylated hemoglobin A1c (HbA1c) 7.0%-10.0% (both inclusive) at screening.~* Treatment with a stable dose of metformin ≥ 1000mg/day for at least 3 months prior to screening.~* Body mass index (BMI) 25 kg/m2-50 kg/m2 (both inclusive) at screening.~* Women of childbearing potential must be ready and able to use highly effective methods of birth control.~Exclusion criteria:~* Patients with type 1 diabetes.~* Exposure to semaglutide, or other Glucagon-like-peptide 1 receptor (GLP-1R) agonists (including combination products) within 3 months prior to screening, or any previous exposure to BI 456906.~* Any additional oral anti-hyperglycemic medication beyond metformin within 3 months prior to screening.~* Use of insulin for glycemic control within 12 months prior to screening.~* Resting Heart Rate \>100 bpm or blood pressure ≥160/95 mmHg at screening.~* A marked baseline prolongation of QT/QTc (Fridericia) interval or any other clinically significant Electrocardiogram (ECG) finding at screening.~* Body weight change of +/- 5% or more in the past 3 months or on anti-obesity therapies at any time during the 6 months prior to screening.~* Continuous oral pharmacotherapy to treat any clinical condition during the Trial. Following medications are allowed:~  * metformin, anti-hypertensives (any medication known to cause heart block or bradycardia such as beta-blockers, verapamil and diltiazem are excluded unless used to treat heart rate control or hypertension),~ * Hormone replacement therapy including thyroid hormone, lipid lowering, proton pump inhibitors, H2 blockers for Gastric esophageal reflux disease (GERD), analgesics,~ * sleep medications~ * antihistamines~ * selective Alpha receptor blocker for benign prostatic hyperplasia Patients must be on a stable dose for at least 3 months Prior to Screening~* Any suicidal behavior in the past 2 years, any suicidal ideation of type 4 or 5 in the Columbia-suicide severity rating scale (C-SSRS) in the past 3 months at screening.~* Chronic or relevant acute infections.~* Women who are pregnant, nursing, or who plan to become pregnant while in the trial.~* Further exclusion criteria apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- BI 456906 0.3 mg (Type: EXPERIMENTAL): None
- BI 456906 0.9 mg (Type: EXPERIMENTAL): None
- BI 456906 1.8 mg (Type: EXPERIMENTAL): None
- BI 456906 2.7 mg (Type: EXPERIMENTAL): None
- BI 456906 1.2 twice weekly (2.4) mg (Type: EXPERIMENTAL): None
- BI 456906 1.8 twice weekly (3.6) mg (Type: EXPERIMENTAL): None
- Semaglutide (Type: ACTIVE_COMPARATOR): None
- Placebo (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).